Results 131 to 140 of about 15,288 (159)

Heterogeneity in Treatment Effects of Reduced Versus Standard Dose of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. [PDF]

Cancer Med
Fukuokaya W, Mori K, Yanagisawa T, Ito K, Urabe F, Rajwa P, Shariat SF, Kimura T, Hirakawa A.   +8 more
europepmc   +1 more source

Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link? [PDF]

Int J Mol Sci
Uivarosi V, Miricescu D, Vacaroiu IA, Spinu DA, Stefani C, Stanciu S, Nica RI, Stanescu-Spinu II, Badoiu SC, Nica S, Jinga V.   +10 more
europepmc   +1 more source

Integrative transcriptomic profiling reveals subtype-specific therapeutic vulnerabilities and resistance mechanisms in prostate cancer. [PDF]

BMC Cancer
Liu W, Kong W, Jiang S, Wei Y, Yu Z, Cao X, Yang J, Wei X, Shen L, Qin C, Zhu Q.   +10 more
europepmc   +1 more source

Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer. [PDF]

Prostate Cancer Prostatic Dis
Freedland SJ, Hong A, El-Chaar N, De Hoedt AM, Kim J, Evans C, Parrish JA, Touya M, Ramaswamy K, Gu L, Polascik TJ.   +10 more
europepmc   +1 more source

Novel Combination of Metronomic Cyclophosphamide and Darolutamide Induces Sustained Clinical Response in Heavily Treated Prostate Cancer with Prostate-Specific Membrane Antigen-Negative Liver Metastases and Rapid Disease Progression. [PDF]

Case Rep Oncol
Patel VM, Cai Q, Ahn R, Hill K, Wang J.
europepmc   +1 more source

Induction of apoptosis and growth inhibition by silodosin and abiraterone acetate in PC-3 human prostate cancer cells. [PDF]

Investig Clin Urol
Hakim L, Rahman ZA, Hidayatullah F, Ng AC.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapy-Related Myeloid Neoplasms After [¹⁷⁷Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

Journal of Nuclear Medicine
[177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) has been described after [177Lu]Lu-DOTATATE but has not, to our knowledge, yet been reported after [177Lu]Lu-PSMA.
Michal, Eifer, Duncan E K, Sutherland, Isaac, Goncalves, James P, Buteau, Lewis, Au, Arun A, Azad, Louise, Emmett, Grace, Kong, Louise, Kostos, Aravind S, Ravi Kumar, Edmond M, Kwan, Elizabeth, Medhurst, Shahneen, Sandhu, Ben, Tran, Alexander W, Wyatt, Michael S, Hofman   +15 more
openaire   +2 more sources

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly